Dmytro Shymkiv forecasts future impact of coronavirus on business
Certain areas of business have suffered a profit decrease up to 80% due to the Covid-19 coronavirus pandemic and related quarantine restrictions. This was stated by Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group.
According to him, only companies capable of adapting can survive in such harsh conditions: those which can adjust to new realities, find new forms of cooperation with customers, actively use innovative technologies and implement IT innovations. According to the forecasts of analysts and experts, in 2021 various digital platforms, instant messengers and chats, delivery services and real estate trade will continue to develop and gain popularity. The construction workers, developers and owners of office space and commercial real estate will face the biggest challenges. The explanation is obvious: remote work reduces the demand for renting an office and shops, but at the same time more and more people want to have at home a separate room for an office or a gym.
According to the top manager, deurbanization is another trend triggered by the coronavirus crisis and quarantines. Urban residents, in order to protect themselves and their loved ones from the risk of being infected, seek to limit the number of social contacts that are inevitable in cities. To do this, they move to the countryside, live there and work remotely.
Despite the crisis, Darnitsa Group continues to actively invest in new research and development. Moreover, the pandemic has sped up the implementation of projects that were previously only talked about. Now the pharmaceutical company “Darnitsa” is systematically introducing the latest IT technologies into its production, working on increasing the number of in silico studies- that is when modeling of biological experiments is carried out entirely in a computer. All this will allow us to be faster and more precise in predicting the consequences of diseases and the outcome of therapy, which means that the pharmaceutical industry will be able to produce new, much more effective drugs with fewer side effects.
As for Darnitsa, Dmytro Shymkiv said that the company is currently working on more than 50 names of drugs, which are at various stages of development and research. Their official registration is scheduled for 2023. Most of these medicines address pain, heart and nervous system problems.